This study evaluated minimal residual disease (MRD) 3 months post-transplantation in 106 multiple myeloma patients using next-generation sequencing (NGS, LymphoTrack®) and next-generation flow (NGF, EuroFlow). NGS had limitations due to sample processing, but showed high correlation with NGF (R² = 0.905). Three-year progression-free survival (PFS) and overall survival (OS) were significantly better for MRD-negative patients by both methods. Cox regression showed similar prognostic value for NGS and NGF negativity in predicting PFS and OS. The findings highlight the importance of MRD detection in predicting myeloma patient outcomes.
Publisher
Blood Cancer Journal
Published On
Oct 30, 2020
Authors
Alejandro Medina, Noemi Puig, Juan Flores-Montero, Cristina Jimenez, M. Eugenia Sarasquete, Maria Garcia-Alvarez, Isabel Prieto-Conde, Carmen Chillon, Miguel Alcocer, Norma C. Gutierrez, Albert Oriol, Laura Rosinol, Joan Blade, Mercedes Gironella, Miguel T. Hernandez, Veronica Gonzalez-Calle, Maria-Teresa Cederna, Bruno Paiva, Jesus F. San-Miguel, Juan-Jose Lahuerta, Maria-Victoria Mateos, Joaquin Martinez-Lopez, Alberto Orfao, Marcos Gonzalez, Ramon Garcia-Sanz
Tags
minimal residual disease
multiple myeloma
next-generation sequencing
survival outcomes
MRD-negative
Related Publications
Explore these studies to deepen your understanding of the subject.
